Chronic pain after surgery, also known as chronic postsurgical pain (CPSP), is recognized as a significant public health issue with serious medical and economic consequences. Current research on CPSP ...

The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

Kang et al. present HCAD, a peripherally restricted DREADD based on HCA2, with a chemical actuator that avoids crossing the blood-brain barrier and selectively reduces pain in mice. This system will enable the study of peripheral physiology without affecting the central nervous system.